Beacon Targeted Therapies Launches Its Latest Clinical Trial and Drug Database Solution - Beacon Gene Therapy

LONDON, May 26, 2020 /PRNewswire/ -- Beacon Targeted Therapies, a Hanson Wade Ltd company, is a leader in bespoke and tailored clinical trial and drug development database products in targeted therapies providing accurate, in-depth, and real-time information on the rapidly evolving drug development landscapes.

Today we announce the launch of our latest database solution - Beacon Gene Therapy, which addresses the growing <s> </s>demands on accurately tracking the gene therapy space with the latest scientific and technological innovations and monitoring competitors.

Our sector-specific, modular solution brings together all publicly known available sources of data on gene therapies and houses them under one repository. It is manually curated and includes clinical trial and drug records for preclinical, active, approved, and discontinued assets for all types of therapies where the gene/genetic material is being transferred to the patient, either through cell-free or cell-based mechanisms, aimed at treating non-oncology indications.

Beacon Gene Therapy Includes:

    --  Viral and non-viral vector-based therapies
    --  Modified cell therapies
    --  Antisense or other naked DNA/RNA technologies
    --  DNA/RNA based vaccines
    --  Empty Vector Trials

Beacon Gene Therapy allows you to search the clinical trial and drug landscape by:

    --  Gene/mutation
    --  Editing technology (CRISPR/Cas9, Cas-CLOVER, etc.)
    --  Gene delivery system
    --  Route of Administration
    --  and over 20 other search parameters

Allowing you to cut through the noise and focus in on the literature and insights you need for evidence decision-making on your drug development programs.

Our sources cover (but are not limited to):

    --  Clinical Trials Registries
    --  Scientific Journals and Publications
    --  Company Reports and Presentations
    --  Press Releases
    --  Conference Reports and Abstracts
    --  Government and Regulatory Organizations
    --  Newspapers and other media
    --  Patents

"Beacon is in a unique position to provide drug developers in the gene therapy space a complete clinical trial and drug development pipeline overview. To keep up with the many technological innovations and challenges in the space such as immunogenicity." - Curtis Dingley - Commercial Director, Beacon Targeted Therapies

For more information the Beacon Gene Therapy database solution, please visit:

About Beacon Targeted Therapies:

Beacon Targeted therapies is a Hanson Wade Ltd company - a world leader in conference and data products in high growth industries. Beacon Targeted Therapies is a clinical trial and pipeline database solution, designed in partnership with pharmaceutical professionals, tracking targeted therapies to provide accurate, in-depth, and real-time information in the rapidly evolving landscape of drug development.

For Media Enquiries:
J-Ney Antique
Beacon Targeted Therapies - Hanson Wade

View original content:

SOURCE Beacon Targeted Therapies